Network X 2025 Agenda Highlights the Future of Telecom on Expo Floor
24.9.2025 10:00:00 CEST | Business Wire | Press Release
When the global telecom industry gathers in Paris for Network X 2025 (October 14 - 16), attendees can expect more than keynote speeches and panel debates. This year’s edition unites the sector’s most influential players under one roof with an interactive expo floor and new event features. From AI-powered broadband networks and 5G monetisation to sustainable infrastructure and satellite connectivity, leading technology sponsors, live demonstrations and dynamic stage presentations will showcase the innovations shaping Europe’s digital future.
The show floor is designed to immerse attendees in the latest telecom technologies transforming society. Industry giants and innovators, including Nokia, Huawei, Adtran, Intel, Qualcomm, ZTE and Ciena, alongside dozens of startups, will offer hands-on demos bringing fresh ideas and practical solutions to the ecosystem.
Special event features curated for the Network X 2025 agenda include:
- Wireless Global Congress EMEA by WBA (October 13-16): The Wireless Broadband Alliance (WBA) co-locates for the third consecutive year, bringing the Wireless Global Congress EMEA, the home of the largest Wi-Fi technology event.
- UBBF 2025 (October 13-14): As the world's premier ultra-broadband industry, Huawei proudly presents the 11th Ultra-Broadband Forum (UBBF 2025).
- BDC by WBBA (October 14): The annual Broadband Development Congress by the World Broadband Association (BDC by WBBA) explores how telcos can lead the development of sovereign, future-ready infrastructure that enables AI-driven services, attracts strategic investment, and supports sustainable economic development.
- Data Center World at Network X (October 14-16): A three-day programme focused on data centre investments in IT and digital infrastructure to support the burgeoning capacity demands.
- Network X Awards (October 14): Now in its third year, the Awards celebrate excellence and innovation across Europe’s telecom industry.
In addition to the co-located events, Network X also offers experiences for professionals at every stage of their careers - from those entering the field to established thought leaders. The Emerging Telecom Leaders Programme fosters the next generation of talent by providing a platform for invited telecom speakers and VIPs to nominate an employee, under 30 years of age, to attend this important industry event. Further networking opportunities include the Network X Party, a 5km Run through Paris, and a breakfast briefing with Omdia.
Network X will take place October 14-16 at the Paris Expo Porte de Versailles and presented in thanks to sponsors, including Qualcomm, Orange, Bitdefender, CIG, Huawei, Nokia, Taara, 1finity, Adtran, Adeptic Reply, Applogic Networks, Aprecomm, Cujo AI, Ericsson, Fibocom, Heights, Intel, Ciena, Ekinops, Ribbon Communications, and Tejas Networks. For further information and to register for the event, visit www.networkxevent.com/.
About Network X
Network X returns to Paris on October 14-16, 2025, at Paris Expo Porte de Versailles as the only global event that unites the fixed and mobile telecom markets. Bringing together over 5,500 senior network infrastructure and service professionals, including 1,500+ operators from telco operators, Network X serves as a hub for industry leaders, technology vendors, policymakers, analysts, and media. The 2025 event will explore five key themes shaping the future of connectivity: Fibre, Wi-Fi Networks and Services, Optical Transport, Mobile Networks, Mobile Services and Data Centres.
With a focus on monetising next-generation fixed, mobile, satellite and transport networks through AI and cloud, Network X provides a comprehensive platform for professionals to learn, engage, and network with experts, technology providers, and peers across the telecommunications landscape. www.networkx.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20250923812117/en/
Contacts
Media Contact:
Suzanne Matulay
networkx@society32.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom